Suppr超能文献

相似文献

1
Mutations in and genes are associated with specific alterations of the immune system in myelofibrosis.
Oncoimmunology. 2017 Jul 5;6(10):e1345402. doi: 10.1080/2162402X.2017.1345402. eCollection 2017.
3
Somatic mutations of calreticulin in myeloproliferative neoplasms.
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
5
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.
6
Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Br J Haematol. 2017 Apr;177(1):55-66. doi: 10.1111/bjh.14512. Epub 2017 Feb 7.
7
[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):151-156. doi: 10.7534/j.issn.1009-2137.2017.01.027.
8
Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Hematology. 2017 Dec;22(10):599-606. doi: 10.1080/10245332.2017.1312736. Epub 2017 Apr 13.
9
ASXL1 mutations in Chinese patients with essential thrombocythemia.
Exp Ther Med. 2018 May;15(5):4149-4156. doi: 10.3892/etm.2018.5939. Epub 2018 Mar 9.

引用本文的文献

1
Monocyte Involvement in the Pathogenesis of Myeloproliferative Neoplasms.
Int J Mol Sci. 2025 Jul 3;26(13):6422. doi: 10.3390/ijms26136422.
2
Potential application of the bulk RNA sequencing in routine MPN clinics.
BMC Cancer. 2025 Apr 22;25(1):746. doi: 10.1186/s12885-025-13947-x.
3
Intersecting Pathologies: Polycythemia Vera and Recurrent Infections in an Elderly Patient.
Cureus. 2025 Mar 4;17(3):e80029. doi: 10.7759/cureus.80029. eCollection 2025 Mar.
4
Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis.
Haematologica. 2025 Apr 1;110(4):938-951. doi: 10.3324/haematol.2024.285598. Epub 2024 Oct 10.
5
Immune-dysregulation harnessing in myeloid neoplasms.
Cancer Med. 2024 Sep;13(17):e70152. doi: 10.1002/cam4.70152.
6
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Int J Mol Sci. 2023 Dec 12;24(24):17383. doi: 10.3390/ijms242417383.
7
Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Future Oncol. 2024;20(17):1165-1174. doi: 10.2217/fon-2022-1256. Epub 2023 Nov 22.

本文引用的文献

2
Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis.
Blood. 2016 Sep 22;128(12):1660-2. doi: 10.1182/blood-2016-03-704577. Epub 2016 Aug 16.
3
ILC2s masquerade as ILC1s to drive chronic disease.
Nat Immunol. 2016 May 19;17(6):611-2. doi: 10.1038/ni.3467.
4
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Leuk Res. 2016 Apr;43:39-43. doi: 10.1016/j.leukres.2016.02.004. Epub 2016 Feb 16.
7
Innate lymphoid cells in the initiation, regulation and resolution of inflammation.
Nat Med. 2015 Jul;21(7):698-708. doi: 10.1038/nm.3892. Epub 2015 Jun 29.
8
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.
Br J Haematol. 2015 Oct;171(1):60-73. doi: 10.1111/bjh.13519. Epub 2015 Jun 15.
9
Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.
PLoS One. 2015 Mar 20;10(3):e0116723. doi: 10.1371/journal.pone.0116723. eCollection 2015.
10
CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
Haematologica. 2015 Jul;100(7):e257-60. doi: 10.3324/haematol.2014.119602. Epub 2015 Feb 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验